KR100743861B1 - 솔잎 추출물을 함유하는 바이러스로 인한 인간 질환의 치료및 예방용 조성물 - Google Patents
솔잎 추출물을 함유하는 바이러스로 인한 인간 질환의 치료및 예방용 조성물 Download PDFInfo
- Publication number
- KR100743861B1 KR100743861B1 KR1020060101690A KR20060101690A KR100743861B1 KR 100743861 B1 KR100743861 B1 KR 100743861B1 KR 1020060101690 A KR1020060101690 A KR 1020060101690A KR 20060101690 A KR20060101690 A KR 20060101690A KR 100743861 B1 KR100743861 B1 KR 100743861B1
- Authority
- KR
- South Korea
- Prior art keywords
- virus
- delete delete
- extract
- pine
- pine needle
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 287
- 239000000284 extract Substances 0.000 title claims abstract description 223
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 21
- 235000008331 Pinus X rigitaeda Nutrition 0.000 title abstract description 194
- 241000018646 Pinus brutia Species 0.000 title abstract description 194
- 235000011613 Pinus brutia Nutrition 0.000 title abstract description 194
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 51
- 201000010099 disease Diseases 0.000 title abstract description 50
- 239000000203 mixture Substances 0.000 title abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 81
- 241000287828 Gallus gallus Species 0.000 claims abstract description 43
- 241000711404 Avian avulavirus 1 Species 0.000 claims abstract description 36
- 241000712909 Reticuloendotheliosis virus Species 0.000 claims abstract description 25
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 23
- 241001519465 Avian metapneumovirus Species 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims abstract description 9
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims abstract description 6
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 98
- 208000015181 infectious disease Diseases 0.000 claims description 58
- 241000712461 unidentified influenza virus Species 0.000 claims description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- 206010064097 avian influenza Diseases 0.000 claims description 31
- 208000024891 symptom Diseases 0.000 claims description 29
- 230000000241 respiratory effect Effects 0.000 claims description 28
- 206010022000 influenza Diseases 0.000 claims description 25
- 230000002458 infectious effect Effects 0.000 claims description 18
- 241000282898 Sus scrofa Species 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 206010035664 Pneumonia Diseases 0.000 claims description 10
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 8
- 208000023504 respiratory system disease Diseases 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 240000007263 Pinus koraiensis Species 0.000 claims description 7
- 235000011615 Pinus koraiensis Nutrition 0.000 claims description 7
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 7
- 241000218686 Pinus thunbergii Species 0.000 claims description 6
- 235000008585 Pinus thunbergii Nutrition 0.000 claims description 6
- 230000001850 reproductive effect Effects 0.000 claims description 6
- 240000008670 Pinus densiflora Species 0.000 claims description 5
- 235000000405 Pinus densiflora Nutrition 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims description 4
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 4
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 201000006476 shipyard eye Diseases 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 241000711920 Human orthopneumovirus Species 0.000 claims description 3
- 208000002077 Coxsackievirus Infections Diseases 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 208000009602 Human Adenovirus Infections Diseases 0.000 claims 2
- 238000002474 experimental method Methods 0.000 abstract description 23
- 230000000840 anti-viral effect Effects 0.000 abstract description 19
- 241000711450 Infectious bronchitis virus Species 0.000 abstract description 15
- 230000036541 health Effects 0.000 abstract description 15
- 238000001727 in vivo Methods 0.000 abstract description 13
- 241001465754 Metazoa Species 0.000 abstract description 8
- 241000712431 Influenza A virus Species 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 3
- 238000012404 In vitro experiment Methods 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 238000010790 dilution Methods 0.000 description 151
- 239000012895 dilution Substances 0.000 description 151
- 238000000338 in vitro Methods 0.000 description 92
- 239000000469 ethanolic extract Substances 0.000 description 71
- 229960005486 vaccine Drugs 0.000 description 71
- 230000009467 reduction Effects 0.000 description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 56
- 238000012360 testing method Methods 0.000 description 39
- 240000005020 Acaciella glauca Species 0.000 description 36
- 235000018782 Dacrydium cupressinum Nutrition 0.000 description 36
- 235000013697 Pinus resinosa Nutrition 0.000 description 36
- 230000003253 viricidal effect Effects 0.000 description 35
- 241000271566 Aves Species 0.000 description 33
- 235000013330 chicken meat Nutrition 0.000 description 33
- 230000000694 effects Effects 0.000 description 29
- 239000012153 distilled water Substances 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- 230000003612 virological effect Effects 0.000 description 27
- 238000002255 vaccination Methods 0.000 description 25
- 239000002609 medium Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 24
- 208000002979 Influenza in Birds Diseases 0.000 description 23
- 239000000843 powder Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 18
- 208000010359 Newcastle Disease Diseases 0.000 description 18
- 230000006378 damage Effects 0.000 description 18
- 238000011081 inoculation Methods 0.000 description 18
- 239000013642 negative control Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 230000001717 pathogenic effect Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 230000000120 cytopathologic effect Effects 0.000 description 14
- 235000013601 eggs Nutrition 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000007865 diluting Methods 0.000 description 12
- 239000012454 non-polar solvent Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 241000709687 Coxsackievirus Species 0.000 description 11
- 241000282887 Suidae Species 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 241001474374 Blennius Species 0.000 description 10
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 210000003128 head Anatomy 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 244000144977 poultry Species 0.000 description 9
- 235000013594 poultry meat Nutrition 0.000 description 9
- 241000272517 Anseriformes Species 0.000 description 8
- 238000000729 Fisher's exact test Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 241001500351 Influenzavirus A Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000711902 Pneumovirus Species 0.000 description 8
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 8
- 210000004534 cecum Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 241001493065 dsRNA viruses Species 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 101710154606 Hemagglutinin Proteins 0.000 description 7
- 102000005348 Neuraminidase Human genes 0.000 description 7
- 108010006232 Neuraminidase Proteins 0.000 description 7
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 7
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 7
- 101710176177 Protein A56 Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 241000709661 Enterovirus Species 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 239000000185 hemagglutinin Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002798 polar solvent Substances 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000286209 Phasianidae Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000002498 deadly effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 231100000572 poisoning Toxicity 0.000 description 5
- 230000000607 poisoning effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000005727 virus proliferation Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000401 methanolic extract Substances 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- 210000002741 palatine tonsil Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000002435 venom Substances 0.000 description 4
- 231100000611 venom Toxicity 0.000 description 4
- 210000001048 venom Anatomy 0.000 description 4
- 208000010370 Adenoviridae Infections Diseases 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 235000005205 Pinus Nutrition 0.000 description 3
- 241000218602 Pinus <genus> Species 0.000 description 3
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 101800001271 Surface protein Proteins 0.000 description 3
- 206010044302 Tracheitis Diseases 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 239000012470 diluted sample Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 201000009837 laryngotracheitis Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 231100000587 neutral red assay Toxicity 0.000 description 3
- 238000002962 plaque-reduction assay Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000003307 reticuloendothelial effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229940023147 viral vector vaccine Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000006740 Aseptic Meningitis Diseases 0.000 description 2
- 235000005638 Austrian pine Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 206010027201 Meningitis aseptic Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 235000008565 Pinus banksiana Nutrition 0.000 description 2
- 235000013264 Pinus jeffreyi Nutrition 0.000 description 2
- 241000204936 Pinus palustris Species 0.000 description 2
- 235000008578 Pinus strobus Nutrition 0.000 description 2
- 241000218626 Pinus sylvestris Species 0.000 description 2
- 235000014030 Podocarpus spicatus Nutrition 0.000 description 2
- 241000220324 Pyrus Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 208000011131 Reticuloendothelial disease Diseases 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 2
- 241000713896 Spleen necrosis virus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011841 epidemiological investigation Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 235000021017 pears Nutrition 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 238000011085 pressure filtration Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- NXLOLUFNDSBYTP-UHFFFAOYSA-N retene Chemical compound C1=CC=C2C3=CC=C(C(C)C)C=C3C=CC2=C1C NXLOLUFNDSBYTP-UHFFFAOYSA-N 0.000 description 2
- 229960000888 rimantadine Drugs 0.000 description 2
- 235000017985 rocky mountain lodgepole pine Nutrition 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- -1 seryl alcohol Chemical compound 0.000 description 2
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 2
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-WYWMIBKRSA-N (-)-quinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1O AAWZDTNXLSGCEK-WYWMIBKRSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZDHCZVWCTKTBRY-UHFFFAOYSA-N 12-hydroxylauric acid Chemical compound OCCCCCCCCCCCC(O)=O ZDHCZVWCTKTBRY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UGAGPNKCDRTDHP-UHFFFAOYSA-N 16-hydroxyhexadecanoic acid Chemical compound OCCCCCCCCCCCCCCCC(O)=O UGAGPNKCDRTDHP-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000035315 Avulavirus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000010711 Cattle disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000709734 Coxsackievirus A24 Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- LIOOJQZRNLJKMU-UHFFFAOYSA-N Demethyl coniferin Natural products OCC=Cc1ccc(OC2OC(CO)C(O)C(O)C2O)c(O)c1 LIOOJQZRNLJKMU-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000336325 Duck infectious anemia virus Species 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241001529459 Enterovirus A71 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 108010062618 Oncogene Proteins v-rel Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- GOZCEKPKECLKNO-RKQHYHRCSA-N Picein Chemical compound C1=CC(C(=O)C)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GOZCEKPKECLKNO-RKQHYHRCSA-N 0.000 description 1
- 235000017339 Pinus palustris Nutrition 0.000 description 1
- 241001236212 Pinus pinaster Species 0.000 description 1
- 235000005097 Pinus roxburghii Nutrition 0.000 description 1
- 235000008582 Pinus sylvestris Nutrition 0.000 description 1
- 208000004692 Pneumovirus Infections Diseases 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 101710119636 Trypsin-5 Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 208000005266 avian sarcoma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- SFLMUHDGSQZDOW-FAOXUISGSA-N coniferin Chemical compound COC1=CC(\C=C\CO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-FAOXUISGSA-N 0.000 description 1
- LIOOJQZRNLJKMU-UXXRCYHCSA-N coniferin Natural products OCC=Cc1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(O)c1 LIOOJQZRNLJKMU-UXXRCYHCSA-N 0.000 description 1
- SFLMUHDGSQZDOW-IBEHDNSVSA-N coniferoside Natural products COC1=CC(C=CCO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-IBEHDNSVSA-N 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 239000002037 dichloromethane fraction Substances 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000009365 direct transmission Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- IKUQEFGEUOOPGY-UHFFFAOYSA-N euoniside Natural products COC1=CC=2C=CC(=O)OC=2C(OC)=C1OC1OC(CO)C(O)C(O)C1O IKUQEFGEUOOPGY-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011239 genetic vaccination Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- SRYDOKOCKWANAE-UHFFFAOYSA-N hexadecane-1,1-diol Chemical compound CCCCCCCCCCCCCCCC(O)O SRYDOKOCKWANAE-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000004726 long-term protective immunity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000029522 neoplastic syndrome Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001839 pinus sylvestris Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000005061 slumber Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940021648 varicella vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000012873 virucide Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
용매 | 사용된 솔잎분말 (g) | 추출 후 회수된 양 (g) | 회수율 (%) |
물 | 80 | 5 | 6.25 |
30% 에탄올 | 80 | 9 | 11.25 |
60% 에탄올 | 80 | 20 | 25 |
100% 에탄올 | 80 | 20 | 25 |
100% 메탄올 | 80 | 20 | 25 |
구분 | 시험관내 살바이러스 효능 | ||
완전감소 | 104 감소 | 102 감소 | |
적송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
해송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
잣나무잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
* 처리 바이러스: Influenza virus H1N1 (105.6 TCID50/㎖) * 처리 추출물 및 처리조건: 60 % 에탄올 추출물, 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | ||
완전감소 | 104 감소 | 102 감소 | |
적송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
해송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
잣나무잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
* 처리 바이러스: Newcastle disease virus (105.6 TCID50/㎖) * 처리 추출물 및 처리조건: 60 % 에탄올 추출물, 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | ||
완전감소 | 104 감소 | 102 감소 | |
적송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
해송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
잣나무잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
* 처리 바이러스: Infectious bronchitis virus (105.6 TCID50/㎖) * 처리 추출물 및 처리조건: 60 % 에탄올 추출물, 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | ||
완전감소 | 104 감소 | 102 감소 | |
적송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
해송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
잣나무잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
* 처리 바이러스: Avian pneumovirus (105.6 TCID50/㎖) * 처리 추출물 및 처리조건: 60 % 에탄올 추출물, 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | ||
완전감소 | 104 감소 | 102 감소 | |
적송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
해송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
잣나무잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
* 처리 바이러스: PRRS virus (105.6 TCID50/㎖) * 처리 추출물 및 처리조건: 60 % 에탄올 추출물, 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | ||
완전감소 | 104 감소 | 102 감소 | |
적송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
해송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
잣나무잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
* 처리 바이러스: Coxsakie virus (105.6 TCID50/㎖) * 처리 추출물 및 처리조건: 60 % 에탄올 추출물, 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | ||
완전감소 | 104 감소 | 102 감소 | |
적송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
해송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
잣나무잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
* 처리 바이러스: Reticuloendotheliosis virus (105.6 TCID50/㎖) * 처리 추출물 및 처리조건: 60 % 에탄올 추출물, 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | ||
완전감소 | 104 감소 | 102 감소 | |
적송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
해송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
잣나무잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
* 처리 바이러스: Aujeszky's disease virus (105.6 TCID50/㎖) * 처리 추출물 및 처리조건: 60 % 에탄올 추출물, 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | ||
완전감소 | 104 감소 | 102 감소 | |
적송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
해송잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
잣나무잎 추출물 | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) | 500배 희석 (500 ㎍/㎖) |
* 처리 바이러스: Adeno virus (105.6 TCID50/㎖) * 처리 추출물 및 처리조건: 60 % 에탄올 추출물, 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | |||||||
완전감소 | 102 감소 | |||||||
추출 용매별 추출물 | 100 % 에탄올 추출물 | 60 % 에탄올 추출물 | 30 % 에탄올 추출물 | 열수 추출물 | 100 % 에탄올 추출물 | 60 % 에탄올 추출물 | 30 % 에탄올 추출물 | 열수 추출물 |
추출물 처리 농도 | 2000배 희석 (500 ㎍) | 16000배 희석 (62.5 ㎍) | 4000배 희석 (250 ㎍) | 1000배 희석 (1 ㎎) | 8000배 희석 (125 ㎍) | 32000배 희석 (31.25 ㎍) | 16000배 희석 (62.5 ㎍) | 2000배 희석 (500 ㎍) |
* 처리 바이러스: Influenza virus H1N1 (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | |
60% 에탄올 솔잎 추출물 처리농도 | 완전감소 | 102 감소 |
16000배 희석 (62.5㎍) | 32000배 희석 (31.25㎍) | |
* 처리 바이러스: Influenza virus H1N1 (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | |
60% 에탄올 솔잎 추출물 처리농도 | 완전감소 | 102 감소 |
16000배 희석 (62.5㎍) | 32000배 희석 (31.25㎍) | |
* 처리 바이러스: Avian Influenza virus H9N2 (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | |
60% 에탄올 솔잎 추출물 처리농도 | 완전감소 | 102 감소 |
4000배 희석 (250㎍) | 8000배 희석 (125㎍) | |
* 처리 바이러스: Newcastle disease virus KJW strain (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
항바이러스 효과정도 | 완전감소 | 102 감소 |
60% 에탄올 솔잎 추출물 처리농도 | 4000배 희석 (250㎍) | - |
* 처리 바이러스: IBV M41 strain (105.6 EID50/㎖) * 처리조건: 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | |
60% 에탄올 솔잎 추출물 처리농도 | 완전감소 | 102 감소 |
500배 희석 (2㎎) | 2000배 희석 (500㎍) | |
* 처리 바이러스: Avian pneumovirus (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | |
60% 에탄올 솔잎 추출물 처리농도 | 완전감소 | 102 감소 |
500배 희석 (2㎎/㎖) | 2000배 희석 (500㎍/㎖) | |
* 처리 바이러스: Coxsakie virus (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | |
60% 에탄올 솔잎 추출물 처리농도 | 완전감소 | 102 감소 |
4000배 희석 (250㎍/㎖) | 8000배 희석 (125㎍/㎖) | |
* 처리 바이러스: Reticuloendotheliosis virus (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | |
60% 에탄올 솔잎 추출물 처리농도 | 완전감소 | 102 감소 |
4000배 희석 (250㎍/㎖) | 8000배 희석 (125㎍/㎖) | |
* 처리 바이러스: Aujeszky's disease virus (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
구분 | 시험관내 살바이러스 효능 | |
60% 에탄올 솔잎 추출물 처리농도 | 완전감소 | 102 감소 |
100배 희석 (10㎎/㎖) | - | |
* 처리 바이러스: Adeno virus (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
솔잎추출물 분획 | 시험관내 살바이러스 효능 | |
완전감소 | 102 감소 | |
디클로로메탄 (CH2Cl2) 가용성 추출물 | 16000배 희석 (62.5㎍/㎖) | 32000배 희석 (31.25㎍/㎖l) |
에틸아세테이트 (EtOAc) 가용성 추출물 | 1000배 희석 (1㎎/㎖) | 2000배 희석 (500㎍/㎖) |
부탄올 (n-BuOH) 가용성 추출물 | 8000배 희석 (125㎍/㎖) | - |
수 (H2O) 가용성 추출물 | 32000배 희석 (31.25㎍/㎖) | - |
솔잎분말 60% 에탄올 추출물 | 16000배 희석 (62.5㎍/㎖) | 32000배 희석 (31.25㎍/㎖) |
* 처리 바이러스: Influenza virus H1N1 (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
솔잎추출물 분획 | 시험관내 살바이러스 효능 | |
완전감소 | 102 감소 | |
디클로로메탄 (CH2Cl2) 가용성 추출물 | 500배 희석 (2㎎/㎖) | 4000배 희석 (250㎍/㎖l) |
에틸아세테이트 (EtOAc) 가용성 추출물 | 효과없슴 | 효과없슴 |
부탄올 (n-BuOH) 가용성 추출물 | 효과없슴 | 100배 (10㎎/㎖) |
수 (H2O) 가용성 추출물 | 2000배 희석 (500㎍/㎖) | 4000배 희석 (250㎍/㎖l) |
솔잎분말 60% 에탄올 추출물 | 4000배 희석 (250㎍/㎖l) | 8000배 희석 (125㎍/㎖l) |
* 처리 바이러스: Newcastle disease virus KJW strain (105.6 TCID50/㎖) * 처리조건: 4 ℃, 30분 |
동물군 | 접종 두수 | 체중(g) (mean ± SD) | 공격접종 결과A) | PI14 F ) | ||||
임상증상B) | 폐사C) | |||||||
접종전 | 접종후 | Sick | MTOD ) | Dead | MDTE ) | |||
솔잎추출물 처리군 5000배 희석 (0.2 ㎎/㎖) | 10 | 29.533 ±1.9802 | 28.54 ±3.4852 | 7/10 | 4.85 | 4/10 | 5.5 | 1.1 |
양성 대조군 | 10 | 29.523 ±1.6428 | 31.14 ±4.5208 | 10/10 | 4.7 | 7/10 | 5.9 | 1.7 |
음성 대조군 | 10 | 29.418 ±1.9398 | 28.09 ±4.4156 | 0/10 | - | 0/10 | - | 0 |
A) 공격접종주 및 접종량 : 인플루엔자바이러스, IN=106.5 TCID50/dose/50 ㎕ B) 임상증상두수/접종두수 C) 폐사두수/접종두수 D) Mean time of onset clinical signs (day) E) Mean death time (day) F) Pathgenicity index : the mean score per mouse per observation over a 14 day period when each day, mouse are scored 0 if normal, 1 if sick (열, 눈꺼풀, 털, 호흡, 구부린 자세 이상, 위축), 2 if dead |
DPI 처리구 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
솔잎추출물 처리군 5000배 (0.2mg/mL) | 사료 | 2.66 | 1.12 | 1.33 | 1.44 | 1.38 | 1.13 | 1.02 | 1.83 | 2.67 | 3.5 | 3.50 | 4.83 | 4.67 | 3.25 |
음수 | 4.54 | 1.52 | 3.33 | 1.67 | 2.5 | 2.5 | 3.33 | 5.21 | 5.34 | 5.33 | 5.83 | 6.67 | 6.67 | 6.67 | |
양성대조군 | 사료 | 2.25 | 0.95 | 0.72 | 0.88 | 0.63 | 0.67 | 1.08 | 1.33 | 2.23 | 3.67 | 4.30 | 5.33 | 4.67 | 4.30 |
음수 | 2.53 | 1.00 | 1.00 | 0.63 | 0.63 | 0.17 | 0.33 | 2.67 | 3.33 | 3.33 | 6.67 | 6.67 | 6.67 | 6.67 | |
음성대조군 | 사료 | 3,56 | 3.65 | 3.21 | 3.78 | 2.89 | 4.55 | 3.82 | 3.91 | 3.69 | 4.31 | 3.42 | 3.61 | 3.78 | 3.99 |
음수 | 5.21 | 5.43 | 5.12 | 5.56 | 5.67 | 5.32 | 5.65 | 5.43 | 5.87 | 5.78 | 5.89 | 5.45 | 5.65 | 5.92 |
투여물 | 조성(mg/kg/day) | 공격접종 역가(CCID50/ml) | 체중(g) (mean±SD) | 공격접종 결과 | ||
생존율A | ||||||
접종전 | 접종후 | 폐사수/총두수 | MDTB±SD | |||
솔잎추출물 | 10 | 103.0 | 21.1±1.4 | 13.1±1.0 | 3/10* | 8.7±0.6 |
식염수 | - | 20.7±0.8 | 14.6±1.2 | 14/20 | 11.8±3.0 | |
A 생존두수/접종두수 B Mean death time(day) *P<0.05 by Fisher's exact test(식염수 처리군 대비) |
투여물 및 조성(mg/kg/day) | 공격접종 역가(CCID50/ml) | 평균병변지수(Mean lung parameters) | ||||||
Day 3 | Day 6 | |||||||
경화도A ±S.D | 무게 (mg±S.D.) | 바이러스역가(log10/g±S.D.) | 경화도A±S.D | 무게(mg±S.D.) | 바이러스역가(log10/g±S.D.) | |||
솔잎추출물 | 10 | 103.0 | 0.1±0.1 | 140±9* | 4.7±0.5*** | 1.0±0.0** | 209±0 | 4.4±0.8* |
식염수 | - | 0.0±0.0 | 159±7 | 6.8±0.2 | 2.5±0.5 | 212±0 | 5.6±0.4 | |
A 경화도(consolidation); 0(정상) - 4(짙은 보라색) *P<0.05; **P<0.01; ***P<0.001 by Fisher's exact test(식염수 처리군 대비) |
투여물 | 사료 내 농도 (%, w/w) | 공격 접종 후 변화 | |||
바이러스 재분리율 (양성수수/접종수수) | 바이러스 역가 (log10EID50/g± S.D.) | ||||
기도 | 맹장편도 | 기도 | 맹장편도 | ||
솔잎추출물 | 1.0 | 1/8** | 1/8** | 2.1± 0.4** | 3.9± 0.3** |
솔잎추출물 | 0.4 | 3/8* | 3/8* | 2.6± 0.4** | 4.6± 0.7** |
솔잎추출물 | 0.1 | 4/8 | 5/8 | 3.2± 1.1 | 5.0± 0.9 |
증류수 | - | 8/8 | 8/8 | 4.1± 0.5 | 7.5± 1.1 |
* P < 0.05 by Fisher’s exact test ** P < 0.01 by Fisher’s exact test |
바이러스 시료 채취부위 | 솔잎 추출물 투여 농도 | 증류수투여군 | |||
500ug/ml | 250ug/ml | 125ug/ml | |||
배출된 바이러스 역가 (log10TCID50/ml ± S.D) | 구강 | 0 | 0 | 0 | 0 |
총배설강 | 2.56±1.7 | 3.26±0.9 | 3.04±1.5 | 4.05±1.9 |
투여물 | 사료 내 농도 (%, w/w) | 공격접종 후 3일 | 공격접종 후 6일 | ||||||
바이러스 재분리율 (양성수수/접종수수) | 바이러스 역가 (log10EID50/g) | 바이러스 재분리율 (양성수수/접종수수) | 바이러스 역가 (log10EID50/g) | ||||||
기도 | 맹장편도 | 기도 | 맹장편도 | 기도 | 맹장편도 | 기도 | 맹장편도 | ||
솔잎추출물 | 1.0 | 2/8* | 0/8 | 2.3** | 0 | 0/8 | 1/8** | 0 | 2.1** |
솔잎추출물 | 0.4 | 4/8 | 0/8 | 3.3* | 0 | 0/8 | 2/8* | 0 | 2.1** |
솔잎추출물 | 0.1 | 4/8 | 0/8 | 3.8 | 0 | 0/8 | 2/8* | 0 | 2.7* |
증류수 | - | 7/8 | 0/8 | 5.6 | 0 | 0/8 | 7/8 | 0 | 4.1 |
* P < 0.05 by Fisher’s exact test ** P < 0.01 by Fisher’s exact test |
Claims (37)
- 적송 (Pinus densiflora Sieb. et Zucc.), 해송 (Pinus thunbergii parlatore) 또는 잣나무 (Pinus koraiensis Sieb. et Zucc) 잎의 에탄올, 디클로로메탄 또는 에틸 아세테이트 가용 추출물을 유효성분으로 함유하는 H1N1, H9N2 또는 H6N5의 혈청형을 가진 인플루엔자 바이러스 (influenza virus)로 인한 독감, 조류독감 또는 변이형 감염성 조류독감, 뉴캐슬병 바이러스 (newcastle disease virus)로 인한 파라인플루엔자(Parainfluenza) 또는 사람 알에스바이러스 감염증 (Respiratory syncytial virus), 닭 전염성 기관지염 바이러스 (infectious broncheitis virus)로 인한 중증급성호흡기증후군(Severe Acute Respiratory Syndrome: SARS), 조류 폐렴바이러스 (avian pneumovirus)로 인한 조류 폐렴 바이러스 감염증, 돼지 생식기 및 호흡 증후군 바이러스 (porcine reproductive and respiratory syndrome virus)로 인한 돼지 생식기 및 호흡 증후군 바이러스 감염증, 콕사키 바이러스 (coxsakie virus)로 인한 콕사키바이러스 감염증, 세망내피증 바이러스 (reticuloendotheliosis virus)로 인한 사람 후천성면역결핍증 바이러스 1형 및 2형 (human immunodeficiency virus type 1 & 2), 오제스키 바이러스 (aujeszky's disease virus)로 인한 사람 단순포진 바이러스 (herpes simplex virus)감염증 또는 사람 허피스 바이러스 6, 6A, 6B, 7형 (human herpesvirus 6, 6A, 6B, 7), 또는 아데노 바이러스 (adeno virus)로 인한 호흡기 감염증 또는 유행성 각결막염 (Epidemic keratoconjunctivitis)을 유발하는 사람 아데노 바이러스 감염증의 예방 및 치료용 약학 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제 1항의 적송 (Pinus densiflora Sieb. et Zucc.), 해송 (Pinus thunbergii parlatore) 또는 잣나무 (Pinus koraiensis Sieb. et Zucc) 잎의 에탄올, 디클로로메탄 또는 에틸 아세테이트 가용 추출물을 유효성분으로 함유하는 H1N1, H9N2 또는 H6N5의 혈청형을 가진 인플루엔자 바이러스 (influenza virus)로 인한 독감, 조류독감 또는 변이형 감염성 조류독감, 뉴캐슬병 바이러스 (newcastle disease virus)로 인한 파라인플루엔자(Parainfluenza) 또는 사람 알에스바이러스 감염증 (Respiratory syncytial virus), 닭 전염성 기관지염 바이러스 (infectious broncheitis virus)로 인한 중증급성호흡기증후군(Severe Acute Respiratory Syndrome: SARS), 조류 폐렴바이러스 (avian pneumovirus)로 인한 조류 폐렴 바이러스 감염증, 돼지 생식기 및 호흡 증후군 바이러스 (porcine reproductive and respiratory syndrome virus)로 인한 돼지 생식기 및 호흡 증후군 바이러스 감염증, 콕사키 바이러스 (coxsakie virus)로 인한 콕사키바이러스 감염증, 세망내피증 바이러스 (reticuloendotheliosis virus)로 인한 사람 후천성면역결핍증 바이러스 1형 및 2형 (human immunodeficiency virus type 1 & 2), 오제스키 바이러스 (aujeszky's disease virus)로 인한 사람 단순포진 바이러스 (herpes simplex virus)감염증 또는 사람 허피스 바이러스 6, 6A, 6B, 7형 (human herpesvirus 6, 6A, 6B, 7), 또는 아데노 바이러스 (adeno virus)로 인한 호흡기 감염증 또는 유행성 각결막염 (Epidemic keratoconjunctivitis)을 유발하는 사람 아데노 바이러스 감염증의 예방 및 개선용 건강기능식품.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2006/004258 WO2007046642A1 (en) | 2005-10-19 | 2006-10-19 | Composition comprising an extract of pine needle for preventing and treating human disease caused by viruses and the use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050098791 | 2005-10-19 | ||
KR20050098791 | 2005-10-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070042895A KR20070042895A (ko) | 2007-04-24 |
KR100743861B1 true KR100743861B1 (ko) | 2007-07-30 |
Family
ID=38177581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060101690A KR100743861B1 (ko) | 2005-10-19 | 2006-10-19 | 솔잎 추출물을 함유하는 바이러스로 인한 인간 질환의 치료및 예방용 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100743861B1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101103345B1 (ko) * | 2009-04-16 | 2012-01-11 | 한국화학연구원 | 세스퀴터펜계 화합물을 함유하는 미세조류 방제용 조성물 |
KR20210133861A (ko) | 2020-04-28 | 2021-11-08 | 서울대학교산학협력단 | 소나무 송지 추출물 또는 이로부터 분리한 다이테르페노이드계 화합물을 유효성분으로 포함하는 돼지 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR102402794B1 (ko) | 2021-11-15 | 2022-05-26 | 한국수목원정원관리원 | 소나무 목부로부터 추출한 오일을 유효성분으로 함유하는 항바이러스 조성물 |
KR20220076565A (ko) | 2020-11-30 | 2022-06-08 | 서울대학교산학협력단 | 백지(Angelica dahurica), 울금(Curcuma longa) 및 송지(Resina Pini) 추출물을 유효성분으로 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR20220102695A (ko) | 2021-01-13 | 2022-07-21 | 서울대학교산학협력단 | 백지(Angelica dahurica), 울금(Curcuma longa) 및 송지(Resina Pini) 추출물을 유효성분으로 포함하는 조류 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101633432B1 (ko) * | 2014-07-24 | 2016-06-24 | 고려대학교 산학협력단 | 감마 허피스바이러스 감염의 개선 및 치료에 사용하기 위한 아까시나무 추출물의 용도 |
CN115607536A (zh) * | 2022-10-12 | 2023-01-17 | 广东省农业科学院动物卫生研究所 | 桉叶素在制备抗猪繁殖与呼吸综合征病毒药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS646218A (en) * | 1987-06-26 | 1989-01-10 | Hiroshi Sakagami | Anti-aids viral agent |
JPH11228433A (ja) | 1998-02-18 | 1999-08-24 | Nobuhiro Suzuki | 消臭性を付与した抗菌剤 |
-
2006
- 2006-10-19 KR KR1020060101690A patent/KR100743861B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS646218A (en) * | 1987-06-26 | 1989-01-10 | Hiroshi Sakagami | Anti-aids viral agent |
JPH11228433A (ja) | 1998-02-18 | 1999-08-24 | Nobuhiro Suzuki | 消臭性を付与した抗菌剤 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101103345B1 (ko) * | 2009-04-16 | 2012-01-11 | 한국화학연구원 | 세스퀴터펜계 화합물을 함유하는 미세조류 방제용 조성물 |
KR20210133861A (ko) | 2020-04-28 | 2021-11-08 | 서울대학교산학협력단 | 소나무 송지 추출물 또는 이로부터 분리한 다이테르페노이드계 화합물을 유효성분으로 포함하는 돼지 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR20220076565A (ko) | 2020-11-30 | 2022-06-08 | 서울대학교산학협력단 | 백지(Angelica dahurica), 울금(Curcuma longa) 및 송지(Resina Pini) 추출물을 유효성분으로 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR20220102695A (ko) | 2021-01-13 | 2022-07-21 | 서울대학교산학협력단 | 백지(Angelica dahurica), 울금(Curcuma longa) 및 송지(Resina Pini) 추출물을 유효성분으로 포함하는 조류 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
KR102402794B1 (ko) | 2021-11-15 | 2022-05-26 | 한국수목원정원관리원 | 소나무 목부로부터 추출한 오일을 유효성분으로 함유하는 항바이러스 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20070042895A (ko) | 2007-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101164515B1 (ko) | 인플루엔자 바이러스 유래 질병의 예방 또는 치료용 조성물 | |
KR100743861B1 (ko) | 솔잎 추출물을 함유하는 바이러스로 인한 인간 질환의 치료및 예방용 조성물 | |
CN101111608A (zh) | 降低疾病传染性的组合物和方法 | |
KR101317318B1 (ko) | 신종인플루엔자, 조류인플루엔자, 일반 및 독감감기, sars 바이러스 억제 효능을 갖는 오배자 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 약학 조성물 | |
US20100189827A1 (en) | Antiviral composition comprising alnus japonica extracts | |
JP5331127B2 (ja) | 榛の木抽出物を含有する抗ウイルス組成物 | |
KR102232733B1 (ko) | 에키네시아 추출물을 포함하는 항바이러스용 조성물 | |
WO2007046643A1 (en) | Composition comprising an extract of pine needle for preventing and treating animal disease caused by viruses and the use thereof | |
KR100743862B1 (ko) | 솔잎 추출물을 함유하는 바이러스로 인한 동물 질환의치료 및 예방용 조성물 | |
KR100769050B1 (ko) | 오리나무 추출물을 함유하는 항바이러스 조성물 | |
KR20080084992A (ko) | 엘더베리 추출물의 용도 | |
US20100028268A1 (en) | Compositions and Methods For Treating Infectious Bronchitis | |
KR100881035B1 (ko) | 맨드라미 추출물을 함유하는 바이러스로 인한 인간 질환의치료 및 예방용 조성물 | |
KR100597711B1 (ko) | 백화사설초 및 영지버섯 추출물을 함유하는 기능성 조성물 | |
KR100881033B1 (ko) | 맨드라미 추출물을 함유하는 바이러스로 인한 동물 질환의치료 및 예방용 조성물 | |
WO2008074028A1 (en) | Methods for treating and reducing the incidence of newcastle disease | |
CN108186866B (zh) | 金贝口服液在抗病毒中的应用 | |
KR101369100B1 (ko) | 아이비엽 및 황련으로 구성된 복합생약 추출물을 유효성분으로 함유하는 인플루엔자 바이러스 관련 질환의 예방 및 치료용 조성물 | |
JP5713484B2 (ja) | 植物抽出物からなるウイルス感染症の予防及び/又は治療用組成物、それらを有効成分とするウイルス感染症の予防及び/又は治療剤、並びにウイルスの細胞への吸着阻害剤 | |
US7390515B2 (en) | Methods of treating viral infections using berry juice fractions | |
WO2007046642A1 (en) | Composition comprising an extract of pine needle for preventing and treating human disease caused by viruses and the use thereof | |
WO2007066991A1 (en) | Composition comprising an extract of celosia for preventing and treating human disease caused by viruses | |
KR102584927B1 (ko) | 핵산 유래 뉴클레오사이드 아날로그 및 이들의 약학적으로 허용가능한 염을 포함하는 항바이러스용 조성물 | |
KR102570597B1 (ko) | 항인플루엔자 바이러스 효과를 갖는 천연 추출물 및 그 조성물 | |
KR20240065464A (ko) | 단풍잎 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120724 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130717 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140718 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150724 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170718 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180724 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20191205 Year of fee payment: 13 |